Market Place
Sourcing Support
US FDA approves Checkpoint`s skin cancer drug
14 Dec 2024 //
REUTERS
Checkpoint Therapeutics Reports Q3 2024 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
Checkpoint Presents Cosibelimab Results At ESMO 2024
16 Sep 2024 //
GLOBENEWSWIRE
Checkpoint To Present At H.C. Wainwright Conference
04 Sep 2024 //
GLOBENEWSWIRE
Checkpoint Therapeutics Reports Q2 2024 Results And Corporate Updates
12 Aug 2024 //
GLOBENEWSWIRE
FDA Accepts Checkpoint`s BLA Resubmission For Cosibelimab In CSCC
25 Jul 2024 //
GLOBENEWSWIRE
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
15 Jul 2024 //
GLOBENEWSWIRE
Checkpoint Therapeutics Resubmits BLA For Cosibelimab
02 Jul 2024 //
GLOBENEWSWIRE
Checkpoint Therapeutics Announces $12M Registered Direct Offering
02 Jul 2024 //
GLOBENEWSWIRE
Checkpoint Aligns with FDA for Upcoming Cosibelimab BLA Resubmission
24 Jun 2024 //
GLOBENEWSWIRE
Checkpoint Therapeutics To Participate In H.C. Wainwright BioConnect Conference
13 May 2024 //
GLOBENEWSWIRE
Checkpoint Therapeutics Q1 2024 Financials, Corporate Update
10 May 2024 //
GLOBENEWSWIRE
Checkpoint Reports Full-Year 2023 Financial Results & Corporate Highlights
22 Mar 2024 //
GLOBENEWSWIRE
Checkpoint Therapeutics Appointed Amit Sharma to Board of Directors
18 Mar 2024 //
GLOBENEWSWIRE
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering
29 Jan 2024 //
GLOBENEWSWIRE
Checkpoint to Participate in the B. Riley Securities 4th Annual Conference
11 Jan 2024 //
GLOBENEWSWIRE
US FDA declines to approve Checkpoint Therapeutics` skin cancer therapy
19 Dec 2023 //
NASDAQ
Checkpoint Strengthens Intellectual Property Protection for Cosibelimab
05 Dec 2023 //
GLOBENEWSWIRE
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Checkpoint Therapeutics Announces Publication of Cosibelimab Trial Results
18 Oct 2023 //
GLOBENEWSWIRE
Beyond Cancer Presents Positive Data for UNO with Checkpoint Inhibitor Therapy
16 Oct 2023 //
GLOBENEWSWIRE
Checkpoint Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
02 Oct 2023 //
GLOBENEWSWIRE
Checkpoint Therapeutics to Participate in Cantor Global Healthcare Conference
21 Sep 2023 //
GLOBENEWSWIRE
Checkpoint to Present at H.C. Wainwright 25th Annual Global Conference
06 Sep 2023 //
GLOBENEWSWIRE
Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Checkpoint Announces $10 Million Registered Direct Offering Priced At-the-Market
31 Jul 2023 //
GLOBENEWSWIRE
Checkpoint Announces Presentation of New Cosibelimab Pharmacokinetic Data
28 Jun 2023 //
GLOBENEWSWIRE
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering
23 May 2023 //
GLOBENEWSWIRE
Checkpoint Therapeutics Reports 1Q 2023 FYR & Recent Corporate Highlights
15 May 2023 //
GLOBENEWSWIRE
Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering
31 Mar 2023 //
GLOBENEWSWIRE
Checkpoint Therapeutics Reports Full 2022 FYR and Recent Corporate Highlights
30 Mar 2023 //
GLOBENEWSWIRE
Checkpoint Therapeutics Announces FDA Filing Acceptance of BLA for Cosibelimab
02 Mar 2023 //
GLOBENEWSWIRE
Checkpoint Announces $7.5 Million Registered Direct Offering Under Nasdaq Rules
21 Feb 2023 //
GLOBENEWSWIRE
Checkpoint to Participate in the B. Riley Securities Annual Oncology Conference
17 Jan 2023 //
GLOBENEWSWIRE
Checkpoint Announce $7.5M Registered Offering Priced At-the-Market Under Nasdaq
15 Dec 2022 //
GLOBENEWSWIRE
Checkpoint Therapeutics Announces Reverse Stock Split
05 Dec 2022 //
GLOBENEWSWIRE
Checkpoint Therapeutics Reports 3Q 2022 Financial Results & Corporate Highlights
08 Nov 2022 //
GLOBENEWSWIRE
Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences
08 Sep 2022 //
GLOBENEWSWIRE
Checkpoint Reports Second Quarter 2022 Financial Results and Recent
12 Aug 2022 //
GLOBENEWSWIRE
With Positive Data, Checkpoint Looks to Add Second Indication to BLA
17 Jun 2022 //
BIOSPACE
Checkpoint Therapeutics to Present Pivotal Trial Results of Cosibelimab
06 Jun 2022 //
GLOBENEWSWIRE
Checkpoint Tx to Participate in the H.C. Wainwright Global Investment Conference
19 May 2022 //
GLOBENEWSWIRE
Checkpoint Receives Pediatric Investigational Plan Waivers for Cosibelimab
13 May 2022 //
GLOBENEWSWIRE
Checkpoint Therapeutics Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Checkpoint Tx Announces Data on Pivotal Trial Results of Cosibelimab
28 Apr 2022 //
GLOBENEWSWIRE
Checkpoint Tx to Present at Virtual Fortress Biotech R&D Summit
04 Apr 2022 //
GLOBENEWSWIRE
Checkpoint Therapeutics Reports Full-Year 2021 Financial Results
28 Mar 2022 //
GLOBENEWSWIRE
Checkpoint Tx Shows +ve Topline Results from RE Trial of Cosibelimab
25 Jan 2022 //
GLOBENEWSWIRE
Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Conference
22 Sep 2021 //
GLOBENEWSWIRE
Checkpoint Surgical Expands Peripheral Nerve Care Portfolio with NeuroShield®
12 Aug 2021 //
BUSINESSWIRE
Checkpoint Therapeutics Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
GLOBENEWSWIRE
Checkpoint Completed Enrollment in Registration-Enabling Trial of Cosibelimab
12 May 2021 //
GLOBENEWSWIRE
Checkpoint Inhibitor Response Prediction Milestone Achieved in KIYATEC Study
11 Mar 2021 //
BUSINESSWIRE
Checkpoint Inhibitor Response Prediction Milestone Achieved in KIYATEC Study
10 Mar 2021 //
BUSINESSWIRE
Samsung Biologics and Checkpoint Expand MFG Partnership for Cosibelimab
02 Nov 2020 //
PRNASIA
Checkpoint Therapeutics Announces $20.0 Million Bought Deal Offering
17 Sep 2020 //
GLOBENEWSWIRE
Checkpoint reads out new interim mCSCC data; Taysha eyes $125M for its flash IPO
17 Sep 2020 //
ENDPOINTS
Checkpoint Therapeutics to Present Cosibelimab Interim Results from Registration
27 Jul 2020 //
GLOBENEWSWIRE
